Stonegate Capital Partners has updated its coverage on Cingulate Inc. (NASDAQ: CING) following the company's latest disclosure regarding the FDA's Complete Response Letter (CRL) for its CTx-1301 New Drug Application (NDA). The CRL, issued by the FDA, centers on specific Chemistry, Manufacturing, and Controls (CMC) information requests, with no clinical safety or efficacy concerns identified. According to Stonegate, this shifts the near-term focus from a PDUFA-driven approval event to a CMC-driven resubmission process, but leaves the core product thesis intact.
The key read-through, in Stonegate's view, is timing rather than product viability. The path forward now depends on completing the requested CMC work, resubmitting to the FDA, and moving through the next review cycle. Importantly, Cingulate disclosed nearly $30 million of cash on hand, which management believes is sufficient to address the FDA's requests, execute the resubmission process, and continue pre-commercial activities into 2027. This balance sheet strength provides a buffer for the company to navigate the resubmission without immediate capital pressure.
Stonegate's update highlights that the CRL does not raise any new safety or efficacy concerns, suggesting that the underlying product profile remains promising. The CMC issues are procedural and technical in nature, common in drug development, and resolvable with additional data and documentation. The company's cash position of approximately $30 million is seen as adequate to fund the necessary work and sustain operations through the resubmission and review period.
For investors, the updated timeline means that approval for CTx-1301 may be delayed, but the likelihood of eventual approval remains unchanged based on the information disclosed. The resubmission process typically takes several months, and the FDA's review of a resubmitted NDA can take up to six months. Cingulate's pre-commercial activities, including manufacturing scale-up and market preparation, can continue in parallel with the CMC work.
Stonegate's coverage reaffirms that Cingulate is well-positioned to address the FDA's requests and move forward. The company's focus on CTx-1301, a potential treatment for attention deficit hyperactivity disorder (ADHD), remains a key value driver. The full announcement with additional details is available on Stonegate's website.
